All companies
Visit website
Aspire BioPharma
OperatingAspire BioPharma, Inc.
Healthcare · Biotech · Founded 2021
Disruptive technology that improves medicine effectiveness safely and rapidly
Post-money valuation ⓘ
$352.2M
As of Feb 2024 · from Aspire BioPharma Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$226,792
Across 1 round since 2023
Latest share price
$0.80
Aspire BioPharma Preferred Stock 1 offering price
Financials
FY2021–FY2023 · from SEC filings · hover any figure for its source$0
−$464K
2021
$0
−$597K
2022
$0
−$359K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
Income statement
Revenue
$0
$0
$0
Cost of goods sold
$0
$0
$0
Net income
-$464,173
-$597,117
-$359,071
Taxes paid
$626
$626
$481
Balance sheet
Cash
$185,496
$38
$11,174
Accounts receivable
$0
$0
$0
Total assets
$185,496
$4,917,644
$5,017,181
Short-term debt
$117,169
$193,881
$652,490
Long-term debt
$0
$3,852,552
$3,852,552
Total liabilities
$117,169
$4,046,433
$4,505,042
Other
Headcount
—
0
0
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$352.2M
post-money
Aspire BioPharma Preferred Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $226.8K / $5MInvestors 138Post-money $352.2M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 3 annual reports (FY2023–FY2025)
138 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001995528Share price $0.80
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.